COIOSDeep risk insights through multi-disciplinary research across the globe
open monthly planner on wooden desk
Item new Preprint · not peer-reviewed Added

Offering HPV vaccine at 9-10 brought median series completion to 12.2 years

In a cluster-randomised trial in 31 US paediatric practices, offering HPV vaccination at ages 9-10 rather than 11-12 brought median age at series completion forward from 13.3 to 12.2 years.

A two-arm cluster-randomised trial in 31 paediatric practices in Colorado and California compared introducing HPV vaccination at ages 9-10 with the routine 11-12. Median age at series completion was 12.2 years in the earlier-offer arm as compared to 13.3 years in the control arm. Completion by age 13 rose from 45.1% to 61.6%, and tetanus and meningococcal vaccination by age 13 was no lower.

Why it is interesting: Randomised evidence that the age at which the vaccine is offered changes when the series is completed.

Source
medRxiv, 27 September 2026
Paper
Effect of HPV Vaccine Introduction at 9-10 years: A Randomized Clinical Trial
Authors
Kempe A, Vangala S, Albertin C, O’Leary ST, Beaty B, Saville AW et al.
DOI
10.64898/2026.09.24.26363898
Type
Preprint
Design
Two-arm cluster-randomised trial, 31 paediatric practices in Colorado and California, Oct 2021-Apr 2026
Verdict
New finding
Driver
Infection and pandemics
Driver
Cancer

Other drivers in Behavioural science